There are a lot of treatment updates for various malignancies happening seemingly all at once. We had the chance to speak with Laura S. Wood, RN, MSN, OCN, for her take on why these updates are coming so rapidly.
At the 3rd Annual School of Nursing Oncology, Oncology Nursing News® had the chance to sit down with Laura S. Wood, RN, MSN, OCN, renal cancer research coordinator at the Cleveland Clinic Taussig Cancer Center and one of the co-chairs of the School of Oncology Nursing, and discuss why she believes there are currently so many updates for various malignancies and where these updates are going.
So, we're seeing quite a few updates in the treatment options for a variety of malignancies. That really goes back to better understanding the pathobiology of various cancers and understanding the role of the immune system and being able to target, and or reactivate, the immune system and recognizing that that plays a role in all different malignancies. And so, the clinical trial data has really matured and enrollment in clinical trials has increased our ability to answer those questions and identify those treatment options that are appropriate and those that are not appropriate for FDA approval and treatment.
Survival Benefit, Durable Responses Continue at 3 Years With Liso-cel in Second-line LBCL
July 15th 2024Three-year findings from the TRANSFORM trial provide further evidence that liso-cel should be considered as the new standard of care along with other CAR T-cell therapies for patients with primary refractory or relapsed LBCL, an expert said.